The Fertility Industry's Hidden Cost: Who Really Profits?

The Fertility Industry Is a $8 Billion Business — And It's Growing Fast

The fertility industry in the United States generates roughly $8 billion in annual revenue, and private equity has identified it as one of the highest-growth sectors in healthcare. That number is not a coincidence — it is a business strategy. And like most business strategies, it is built on a specific customer profile: affluent, educated women in their late 30s and early 40s who are emotionally motivated, financially capable, and — critically — operating under a severe information asymmetry.

This is not a conversation about whether people should or shouldn't have children. That is deeply personal, and no one is owed an opinion on it from the outside. But the financial mechanics of how the fertility industry operates, who it targets, who it ignores, and what it actually delivers — those are fair game. They are business and money questions, and they deserve the same rigorous scrutiny we'd apply to any other sector where vulnerable consumers are spending tens of thousands of dollars on a product with a statistically low success rate.

Here is what the data shows, what the industry obscures, and what financially literate consumers need to understand before spending a single dollar.

---

IVF Success Rates Are Not What Clinics Market Them to Be

Let's start with the number that should be the headline of every fertility clinic's brochure but rarely is: a woman who begins IVF at age 45 has approximately a 3% chance of delivering a healthy baby using her own eggs. That figure comes from reporting by The Cut, drawing on clinical data — and it is a far cry from the optimistic, possibility-forward language that dominates most fertility marketing.

The gap between marketed hope and clinical reality is not accidental. It is structural. Here is why:

• Private equity ownership incentivises volume, not outcomes. When a clinic is backed by PE investors with a defined exit timeline, the pressure is to maximise patient throughput and revenue per patient — not to counsel someone out of a treatment cycle that is unlikely to work.
• Success rate reporting is inconsistent. Clinics can selectively report data — for example, citing cumulative success rates across multiple cycles rather than per-cycle rates, or including donor-egg pregnancies in headline numbers without clearly labelling them as such.
• Egg freezing is especially oversold. Freezing eggs (oocytes) alone — as opposed to fertilised embryos — carries significantly lower success rates than most marketing implies. The American Society for Reproductive Medicine has historically cautioned against marketing egg freezing as a guaranteed insurance policy, yet that framing dominates social media advertising and even physical advertising in major urban transit hubs.

The comparison to the funeral industry is instructive here. Both sectors catch consumers at peak emotional vulnerability. Both involve high-ticket purchases made under time pressure. And in both, the information advantage sits almost entirely with the provider. The difference is that the fertility industry has a far more sophisticated marketing apparatus — and a much longer runway to extract revenue from a single customer.

---

Celebrity Pregnancies Are Not Clinical Evidence

One of the most consequential distortions in public understanding of fertility comes from celebrity culture. Seeing a 46-year-old public figure announce a pregnancy — accompanied by a glossy magazine shoot — registers in the brain as data. It is not data. It is anecdote at best, and potentially active misdirection at worst.

What a celebrity pregnancy photo does not tell you:

• Whether the pregnancy involved the mother's own eggs or donor eggs
• Whether a surrogate was used
• Whether a donor embryo was transferred
• How many cycles, miscarriages, or failed transfers preceded the announcement
• What the total financial cost was

The fertility industry benefits enormously from this ambiguity. When high-profile women decline to disclose the mechanics of their pregnancies — which is entirely their right — the public default assumption is that it happened naturally or with minimal intervention. That assumption drives demand. Clinics do not correct it. Advertisers amplify it.

For financially literate consumers, the rule here is the same as it would be with any other product: anecdote is not data, celebrity endorsement is not clinical evidence, and aspirational marketing is not a treatment plan.

---

The Class Dimension the Industry Ignores

The fertility industry's marketing focuses heavily on a narrow demographic: upwardly mobile, predominantly white, college-educated women in major metropolitan areas. That is not a coincidence — it reflects both purchasing power and the deliberate targeting decisions of companies optimising for revenue.

But the class dynamics of fertility and parenthood in America run far deeper than who gets targeted by egg-freezing ads. Consider the parallel system operating simultaneously:

• Who is encouraged to have children: Fertility treatments, IVF, surrogacy, and egg freezing are aggressively marketed to affluent women. Insurance coverage, though improving in some states, still leaves a majority of treatment costs as out-of-pocket expenses — meaning access is largely income-dependent.
• Who faces barriers to keeping children: Poor women, women of colour, and Indigenous women face disproportionate rates of family separation, inadequate maternal healthcare, and in historical context, forced sterilisation programmes that continued into the late 20th century.
• Who absorbs the debt: For women who pursue IVF without the resources to fund it outright, the cost — which can range from $15,000 to $30,000 or more per cycle, with multiple cycles often required — is frequently financed through medical credit products that carry high interest rates.

This bifurcated system — aggressively investing in one class's reproductive possibilities while systematically disadvantaging another's — is not an accident of the market. It reflects deeper political and economic assumptions about whose children are considered socially desirable. That is an uncomfortable truth, but it is one grounded in documented history and present policy.

---

What Private Equity Ownership Actually Means for Patients

Private equity's move into fertility clinics follows a playbook used across healthcare: acquire fragmented providers, consolidate operations, standardise (and often reduce) costs, and monetise at exit — typically within a five-to-seven-year horizon. The model is not inherently predatory, but its incentive structure creates specific risks for patients in high-emotion, high-cost medical contexts.

Key dynamics to understand:

• Growth metrics may conflict with patient welfare. A PE-owned clinic that needs to grow revenue 20% year-over-year has different incentives than an independent physician-owned practice.
• Informed consent practices may be inconsistent. There is significant variation in how thoroughly clinics disclose statistical success rates, alternative options (including adoption or donor embryos), and the psychological and physical toll of treatment.
• Exit-driven timelines compress ethical decision-making. When the goal is to maximise enterprise value ahead of a sale, long-term patient relationships and honest counselling about when to stop treatment are less financially rewarding than another cycle.

None of this means every PE-backed clinic operates unethically. Many employ genuinely excellent physicians who prioritise patient outcomes. But the structure matters, and consumers should ask direct questions: Who owns this clinic? What are the per-cycle success rates for my specific age group and diagnosis? What does stopping treatment look like, and when would you recommend it?

---

What Financially Sound Decision-Making Looks Like Here

For anyone navigating fertility decisions — whether that is IVF, egg freezing, surrogacy, or simply evaluating options — the same principles that apply to any major financial decision apply here:

1. Demand age-specific, diagnosis-specific success data. Not cumulative rates. Not rates that include donor eggs. Your age, your eggs, your diagnosis, per cycle.

2. Get a second opinion from a clinic with different ownership. If one clinic is PE-backed, seek a consult at an independent or academic medical centre. Compare what you're told.

3. Understand the full cost model before starting. A single cycle cost is not the total expected cost. Ask for a realistic scenario that includes the statistical probability of needing multiple cycles.

4. Scrutinise egg freezing claims specifically. Ask for published success rate data for frozen egg transfers by age cohort — not general marketing language. The numbers are available and they are sobering.

5. Consider the psychological cost as a financial input. Fertility treatments involve significant hormonal intervention, emotional strain, and time investment. These have real productivity and wellbeing costs that belong in any honest total-cost calculation.

6. Reproductive autonomy and financial autonomy are connected. Access to affordable, honest reproductive healthcare is a financial equity issue. Advocacy for better insurance coverage, transparent pricing, and regulated marketing claims is in every consumer's interest.

---

The Bottom Line

The fertility industry is not monolithic, and many of the professionals within it are genuinely motivated by patient outcomes. But the sector's rapid consolidation under private equity, combined with aggressive marketing to emotionally vulnerable consumers and systematic overstating of success rates, creates conditions that demand higher consumer scepticism — not lower.

Critiquing the business practices of an industry is not the same as attacking the people who use its services. Women navigating infertility deserve accurate information, transparent pricing, and medical counsel that prioritises their wellbeing over clinic revenue. Right now, the structural incentives do not reliably deliver that. Naming that problem clearly is not insensitive — it is necessary.

The conversation about who gets encouraged to have children, who gets the financial infrastructure to do so, and who gets left out of that system entirely is one of the most consequential socioeconomic conversations of our time. The fertility industry sits at the centre of it. It deserves scrutiny proportional to its size, its growth, and its impact on the people it serves.

---

Frequently Asked Questions

What is the actual IVF success rate for women over 40?

Success rates decline sharply with age. According to clinical data cited in reporting by The Cut, a woman beginning IVF at 45 using her own eggs has roughly a 3% chance of a live birth per cycle. Rates are higher for younger women and significantly higher when donor eggs are used — a distinction that is not always clearly communicated in clinic marketing materials.

Why is private equity investing in fertility clinics?

Private equity firms have identified fertility services — particularly treatments for women in their late 30s and beyond — as a high-growth healthcare segment. Key drivers include: the large out-of-pocket cost structure (limiting insurance constraints on pricing), strong demand driven by delayed childbearing trends, and an emotionally motivated consumer base with relatively high willingness to pay. This creates attractive unit economics for investors, though it also creates potential misalignment between investor incentives and patient welfare.

Is egg freezing a reliable fertility insurance policy?

The evidence does not support the 'insurance policy' framing that dominates egg freezing marketing. Freezing unfertilised eggs carries meaningfully lower success rates than freezing fertilised embryos, and outcomes are highly sensitive to the woman's age at the time of freezing, egg quality, and the clinic's laboratory standards. Consumers should request published, age-stratified success rate data for frozen egg transfers — not general promotional claims — before making a decision.

How does the fertility industry's targeting reflect broader economic inequality?

Fertility treatments are predominantly marketed to and financially accessible by affluent, educated women — largely because treatments cost $15,000–$30,000+ per cycle and insurance coverage remains limited. Meanwhile, poor women, women of colour, and Indigenous women in America face disproportionate barriers to safe, supported parenthood — including inadequate maternal healthcare, higher rates of pregnancy-related mortality, and documented historical policies of coerced sterilisation. The fertility industry's focus on one demographic while broader reproductive healthcare inequities persist for others reflects a systemic, class-oriented dimension that market-driven fertility services do not address.

---

This article is for informational purposes only and does not constitute financial or medical advice. Always consult a qualified financial professional and a licensed medical practitioner before making decisions related to fertility treatments or associated expenditures.